NCT05675787View on ClinicalTrials.gov

Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia

PHASE2RecruitingINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

January 6, 2023

Primary Completion Date

August 31, 2025

Study Completion Date

October 31, 2025

Conditions
Atypical Endometrial HyperplasiaEndometrial Carcinoma Stage I
Interventions
DRUG

Medroxyprogesterone acetate + Atorvastatin

MPA (at a dosage of 250-500 mg/day,) + Atorvastatin (at a dosage of 20 mg/day), by mouth,

Trial Locations (1)

100044

RECRUITING

Wang Jianliu, Beijing

All Listed Sponsors
lead

Peking University People's Hospital

OTHER